TEOXANE Laboratories’ Post

View organization page for TEOXANE Laboratories, graphic

20,451 followers

We are thrilled to share an opinion paper published in the Dermatology and Therapy Journal, advancing the diagnosis of late-onset reactions (LORs), the risks for and the management of these potential complications to hyaluronic acid (HA) dermal fillers. HA fillers are widely used in aesthetic medicine for their effectiveness in enhancing facial features and reducing wrinkles. Despite their generally positive benefit/risk profile, Late Onset Reactions (LOR) can occur, making their prevention and prompt management essential for patient well-being. The Complication Assessment and Risk Evaluation (CARE) Board, a group of renowned specialists in aesthetic medicine convened by TEOXANE, has identified three main causes of LOR: 1. Filler Structure: Low molecular weight HA fillers may trigger immune responses. 2. Infections: Bacteria introduced into the skin during injection, due to poor aseptic conditions, or reactivated from dormant states such as biofilms. 3. Patient Immune System Status: Autoimmune diseases or viral infections. To mitigate these risks, proper patient selection, maintaining high-quality standards during injections, and educating patients on post-procedure care are crucial. The authors provide guidelines and recommendations, which include a risk assessment questionnaire and a treatment algorithm, to aid practitioners in preventing and managing LORs, ensuring safer experiences for patients. At Teoxane, we are dedicated to safety and excellence in aesthetic medicine, continually enhancing patient care and upholding the highest industry standards. #Teoxane #AestheticMedicine #DermalFillers #PatientSafety #MedicalExcellence #Innovation

  • No alternative text description for this image
Jen Vittanuova

Clinical Nurse Director | Creator of award-winning Luxury Medical Aesthetics Clinics | Cosmetic Surgery | Non-surgical Aesthetics | Expert Witness

1w

Where would I find a link to this paper please?

Like
Reply

To view or add a comment, sign in

Explore topics